Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

Urinary Bladder Neoplasms, Lung Neoplasms, Urologic Neoplasms

Urinary Bladder Neoplasms, Neoplasm Metastasis

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Adenocarcinoma, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Clinical Trials

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

SunRISe-1

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

TOMBOLA

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

BAYOU

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

NEXT

Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

GEMDOCE

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

RAD-VACCINE

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

ABATE

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Indi-Blade

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

RAIDER

CIK in Treating Patients With Bladder Cancer